Loading...

Hospital-acquired infection Diagnostics Market Expected to Reach $4,311 Million by 2023

 
 

quote The hospital-acquired infections diagnostics market is projected to grow steadily owing to the adoption of the data analytics to improve healthcare facilities. In addition, the market in developing economies is anticipated to grow rapidly due to the increase in occurrence of hospital-acquired infections due to poor sanitation conditions. quote

Sriram Radhakrishnan
Team Lead, Healthcare at AMR.

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, Hospital-acquired infection diagnostics Market by Product, Test Type, Application, Infection Type and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global hospital-acquired infection diagnostics market was valued at $2,571 million in 2016, and is projected to reach $4,311 million by 2023, growing at a CAGR of 7.5% from 2017 to 2023. The urinary tract infections (UTI) segment accounted for maximum share of the total market in 2016.

Access Full Summary at: https://www.alliedmarketresearch.com/hospital-acquired-infection-diagnostics-market

Hospital-acquired infection are contaminations caused by bacteria, viral, and fungal pathogens. These infections are usually acquired in clinical and hospital settings mainly due to an infected patient, outside environment, or from the staff of that facility.

Rise in prevalence of infections from hospitals and clinical settings drive the market. However, the lack of awareness regarding hospital-acquired infection diagnostics impedes the market growth. Moreover, the technological advancements in healthcare sector for the innovation of novel and sophisticated products is projected to create lucrative opportunities for key market players.

Drug resistance testing segment is anticipated to maintain its dominance during the forecast period, accounting for major share of the global hospital-acquired infections diagnostics market. This is due to the benefits drug resistance testing offers such as they are cost-effective when the prevalence of drug resistance in chronically infected patients is low.

Key Findings of the Hospital-acquired Infection Diagnostics Market:

  • The U.S. was the major shareholder in the North America hospital-acquired infection diagnostics market, and accounted for the highest share in 2016.
  • Disease testing is expected to grow at the highest CAGR during 2017-2023.
  • Japan occupied about two-ninths share of the total Asia-Pacific hospital-acquired infections diagnostics market in 2016.whereas, South Korea is expected to grow rapidly registering a CAGR of 8.3% during the forecast period.
  • The immunoassay segment dominated the market in 2016, growing at a CAGR of 5.6% from 2017 to 2023.
  • Molecular diagnostics accounted for about one fourth share of the total market share in 2016 and is expected to grow with a high CAGR of 12.8% during the forecast period.

In 2016, Asia-Pacific and LAMEA collectively accounted for about one fifth share of the global hospital-acquired infection diagnostics market and is expected to continue this trend throughout the forecast period. The key factors driving the market growth include the demand for hospital-acquired infection diagnostics from middle and low-income countries owing to the massive population and increase in prevalence of diseases.

The report provides a comprehensive analysis of the key players operating in the global hospital-acquired infection diagnostics market such as Abbott Laboratories, AdvanDX, Alere Inc., AstraZeneca plc, Bayer Schering Pharma LLC, Becton Dickinson and Company, Cepheid Inc., Roche AG, Daiichi Sankyo, and Hologic, Inc.

The other players in the value chain of the global hospital-acquired infection diagnostics market include GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Meridien, Pfizer, and Seegene.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Shaun Godinho
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com

 
 

First time buyer?
Check offers and discount on this report
To get this report

 
Click Here
 
 

quote Hospital-Acquired Infection Diagnostics Market by Product (Instrument & Reagents and Consumables), Test Type (Molecular Diagnostics, Urinalysis, and Immunoassay), Application (Disease Testing and Drug-Resistance Testing), Infection Type (Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infections (UTI), and Others), and End User (Hospital, Clinics, Ambulatory Surgery Centers (ASC) and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023 quote

View Report
 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers

 

Featured Readings

 
 

Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

 
Get Industry Data Alerts
 

Buy Full Version
"Hospital-acquired infection Diagnostics Market"
Purchase Enquiry